Prostate Cancer Market Business Outlook and Procurement Survey 2023
Prostate Cancer - Newer Antiandrogens & Emerging T
Publicado el en “Negocios”, Idioma — English. 7 páginas.
Rising star Anti Androgens Third generation Antiandrogens- What left for AR-V7 mutants after TOK-001 failure? Más
Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high. This has expanded WW market size of Prostate cancer drugs to $7b in 2016 from $2.5b in 2011. Now nmCRPC, HSPC and Xtandi/Zytiga resistance population are the markets where in new pipeline drugs are under development. Más